X0508 4 2026-02-02 0 0001737287 Allogene Therapeutics, Inc. ALLO 0001835208 Yoshiyama Annie 210 EAST GRAND AVE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Finance 0 Common Stock 2026-02-02 4 S 0 4167 1.72 D 130322 D Stock Option (Right to buy) 1.87 2026-02-02 4 A 0 179691 0 A 2036-02-02 Common Stock 179691 179691 D Restricted Stock Unit 2026-02-02 4 A 0 50827 0 A Common Stock 50827 50827 D Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. /s/Earl Douglas, Attorney-in-Fact 2026-02-04